Rapid molecular diagnosis of arboviral infections has moved from laboratory aspiration to clinical reality. The new Fiocruz diagnostic platform reduces testing turnaround time from 2–5 days to mere hours by employing real-time PCR technology to detect viral nucleic acids during the acute infection phase. This acceleration is particularly significant given that dengue alone infects an estimated 100–400 million people annually, according to the World Health Organization, with many cases remaining unconfirmed due to diagnostic delays in endemic countries. The multiplex capability—detecting dengue, Zika, chikungunya, and yellow fever simultaneously in a single sample—dramatically increases laboratory efficiency while reducing per-specimen costs. Faster confirmation directly improves clinical case management and enables epidemiologists to respond more effectively to emerging outbreaks. Read the full article on GMJ Newsroom.
Was this article helpful?
